Zalunfiban acetate is under clinical development by CeleCor Therapeutics and currently in Phase III for Myocardial Infarction. According to GlobalData, Phase III drugs for Myocardial Infarction have a 65% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Zalunfiban acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Zalunfiban acetate overview

Zalanfiban (RUC-4, zalunfiban acetate) is under investigation for the treatment of ST-segment elevated myocardial infarction and chronic coronary artery disease. The drug candidate is administered through intramuscular and subcutaneous route. It targets integrin alpha IIb beta3 receptor on the surface of human platelets.

CeleCor Therapeutics overview

CeleCor Therapeutics (CeleCor) is a biotechnology company that focused on developing a first-point-of-contact therapy to improve the treatment of serious heart attacks and developed a point of care injectable to treat ST-segment elevated myocardial infarction. CeleCor is headquartered in Del Mar, California, the US.

For a complete picture of Zalunfiban acetate’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.